Response to EGFR/NTRK/MET Co-Inhibition Guided by Paired NGS in Advanced NSCLC With Acquired EGFR L858R/T790M/C797S Mutations
Journal of the National Comprehensive Cancer Network · 2025-02 · 23 (2)
DOI: 10.6004/jnccn.2024.7070 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2025-02. Verfasst von Xue Yang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thoracic Tumor Multimodality Treatment, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Ch…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Protein Kinase Inhibitors, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 46 Literaturangaben.
Abstract (Originalsprache)
EGFR tyrosine kinase inhibitors (TKIs) have significantly improved clinical outcomes for patients with non–small cell lung cancer (NSCLC) harboring EGFR-activating mutations. However, resistance to TKI therapy often develops due to secondary EGFR mutations or the activation of bypass signalling pathways. Next-generation sequencing (NGS) can efficiently identify actionable genetic alterations throughout treatment. MET amplification is a well-established off-target resistance mechanism. Additionally, rarer mechanisms, such as NTRK1 gene fusions, have been reported. This report highlights a case of a 58-year-old male diagnosed with bone-metastatic NSCLC harboring the EGFR L858R mutation. After receiving dacomitinib and almonertinib sequentially, plasma-based NGS revealed the emergence of EGFR T790M-trans-C797S mutations, prompting a switch to a combination therapy of almonertinib and gefitinib. Upon disease progression, repeat NGS identified EGFR T790M-cis&trans-C797S mutations and a novel POT1 :: NTRK3 fusion in the blood. The fusion retained a complete NTRK kinase domain without frameshift variants, making it a target for treatment. Larotrectinib was incorporated into the dual EGFR-TKI regimen, forming a triplet therapy. Although this resulted in grade 3 dermatitis, the condition resolved after discontinuing gefitinib. At multiorgan progression, matched tissue- and plasma-based NGS identified MET amplification. Subsequently, the patient was started on a triple-inhibition regimen targeting EGFR, NTRK, and MET, which achieved a partial response with favorable tolerability. This is the first reported case of a novel, targetable POT1 :: NTRK3 fusion as a potential off-target mechanism mediating EGFR-TKI resistance, occurring alongside MET amplification in a patient with NSCLC harboring acquired EGFR L858R/T790M/C797S mutations. Concomitant inhibition of EGFR, NTRK, and MET was safe and resulted in a significant response, underscoring the importance of precision medicine guided by matched NGS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Thoracic Tumor Multimodality Treatment, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
- Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
- School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
- Genecast Biotechnology Co., Ltd., Wuxi, Jiangsu, China.
- Laboratory of Clinical Cell Therapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Zitieren
APA
Yang, X., Li, X., Yan, J., Liu, Y., Yin, J., Shao, W., Lu, Y., & Xue, J. (2025). Response to EGFR/NTRK/MET Co-Inhibition Guided by Paired NGS in Advanced NSCLC With Acquired EGFR L858R/T790M/C797S Mutations. Journal of the National Comprehensive Cancer Network, 23(2). https://doi.org/10.6004/jnccn.2024.7070
Vancouver
Yang X, Li X, Yan J, Liu Y, Yin J, Shao W, et al. Response to EGFR/NTRK/MET Co-Inhibition Guided by Paired NGS in Advanced NSCLC With Acquired EGFR L858R/T790M/C797S Mutations. Journal of the National Comprehensive Cancer Network. 2025;23(2). doi:10.6004/jnccn.2024.7070
BibTeX
@article{Yang2025,
author = {Yang, Xue and Li, Xintong and Yan, Jiaqi and Liu, Yuanxin and Yin, Jie and Shao, Weikang and Lu, You and Xue, Jianxin},
title = {Response to EGFR/NTRK/MET Co-Inhibition Guided by Paired NGS in Advanced NSCLC With Acquired EGFR L858R/T790M/C797S Mutations},
journal = {Journal of the National Comprehensive Cancer Network},
year = {2025},
volume = {23},
number = {2},
doi = {10.6004/jnccn.2024.7070}
}
EUVIMED